Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.65 |
| ▸ | XDH | P47989 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Catalpol SCHEMBL17231369 | 1.00 | HSP90AA1 (0.65) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| Catalpol SCHEMBL420515 | 1.00 | HSP90AA1 (0.65) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL29478493 | 0.94 | HSP90AA1 (0.59) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL31345813 | 0.91 | HSP90AA1 (0.70) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL20714336 | 0.91 | HSP90AA1 (0.55) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL20382966 | 0.91 | HSP90AA1 (0.55) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| Methylcatalpol SCHEMBL29425882 | 0.88 | HSP90AA1 (0.67) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL10307818 | 0.85 | L3MBTL1 (0.53) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| Catalposide SCHEMBL419598 | 0.79 | HSP90AA1 (1.00) | HSP90AA1XDHL3MBTL1MEN1KMT2A | |
| SCHEMBL20382967 | 0.78 | HSP90AA1 (0.43) | HSP90AA1XDHL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113834881-B | Callicarpa nudiflora identification method | 海南九芝堂药业有限公司 | 2023-10-31 | — | — | CN | claimed |
| EP-4635569-A2 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | Peptron, Inc. (KR) | 2025-10-22 | — | — | EP | disclosed |
| US-12207653-B2 | Carrier system for preparing herbaceous extracts | SISAF LIMITED (GB) | 2025-01-28 | — | — | US | disclosed |
| EP-4493205-A1 | A LOW MOLECULAR WEIGHT COMPOUND FOR USE IN THE TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 3 | Instytut Chemii Bioorganicznej Polskiej Akademii Nauk (PL) | 2025-01-22 | — | — | EP | disclosed |
| EP-3946270-B1 | CARRIER SYSTEM FOR PREPARING HERBACEOUS EXTRACTS | SISAF LTD (GB) | 2024-08-14 | — | — | EP | disclosed |
| CN-113834881-B | Callicarpa nudiflora identification method | 海南九芝堂药业有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023177314-A1 | A LOW MOLECULAR WEIGHT COMPOUND FOR USE IN THE TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 3 | INSTYTUT CHEMII BIOORGANICZNEJ POLSKIEJ AKADEMII NAUK (PL) | 2023-09-21 | — | — | WO | disclosed |
| EP-4188075-A1 | NUTRIENT LOSS REDUCTION METHOD, USES AND PRODUCTS | PGG Wrightson Seeds Limited (NZ) | 2023-06-07 | — | — | EP | disclosed |
| US-20220265563-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | PEPTRON, INC. (KR) | 2022-08-25 | — | — | US | disclosed |
| US-20220174952-A1 | CARRIER SYSTEM FOR PREPARING HERBACEOUS EXTRACTS | SISAF LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| CN-110198721-B | Antibacterial composition containing polyvinylpyrrolidone and sodium dimercaptopropanesulfonate and application thereof | 梅迪德创新研发有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-11273130-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | The United States, as represented by the Secretary Department of Health and Human Services (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3585422-B1 | ANTISEPTIC COMPOSITION COMPRISING UNITHIOL AND DIMETHYLSULFOXIDE, USE OF THE COMPOSITION AND METHOD OF WOUND TREATMENT WITH ITS USE | MEDID INNOVATION DEV LTD (CY) | 2022-02-09 | — | — | EP | disclosed |
| EP-3585399-B1 | ANTISEPTIC COMPOSITION COMPRISING POLYVINYLPYRROLIDONE AND UNITHIOL AND USE OF THE COMPOSITION | MEDID INNOVATION DEV LTD (CY) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022025774-A1 | NUTRIENT LOSS REDUCTION METHOD, USES AND PRODUCTS | PGG WRIGHTSON SEEDS LIMITED (NZ) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265563-A1 | METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM | GLP1R, IAPP, BDNF | HSP90AA1 709/4885XDH 3482/4885L3MBTL1 1960/4885 |
| US-11273130-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | GLP1R, IAPP, BDNF | HSP90AA1 709/4885XDH 3482/4885L3MBTL1 1960/4885 |
| US-12207653-B2 | Carrier system for preparing herbaceous extracts | FUCA2, HPSE, ALG1 | HSP90AA1 581/4885XDH 4480/4885L3MBTL1 4785/4885 |
| US-20220174952-A1 | CARRIER SYSTEM FOR PREPARING HERBACEOUS EXTRACTS | FUCA2, HPSE, ALG1 | HSP90AA1 581/4885XDH 4480/4885L3MBTL1 4785/4885 |
| US-11771657-B2 | Methods of delivering a neuroprotective polypeptide to the central nervous system | GLP1R, IAPP, BDNF | HSP90AA1 709/4885XDH 3482/4885L3MBTL1 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.